logo

Last Update

This profile was last updated on 8/12/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mitchell Gold?

Mitchell H. Gold

Chief Executive Officer

Dendreon Corporation

HQ Phone:  (206) 256-4545

Direct Phone: (206) ***-****direct phone

Email: m***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Dendreon Corporation

1301 2Nd Ave. Suite 3200

Seattle, Washington,98101

United States

Company Description

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, en...more

Web References(184 Total References)


Team | Alpine Bioventures

www.alpinebioventures.com [cached]

Mitchell H. Gold, MD
Founder & Managing Partner Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold's career in medicine and desire to transform scientific breakthroughs into a reality for patients. As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Read more Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Cascadian Therapeutics (NASDAQ:CASC) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. A Chicago native, Dr. Gold graduated from the University of Wisconsin and Rush University Medical School in Chicago and was a urology resident at the University of Washington. Dr. Gold is on Twitter @Alpine_Mitch


Team | Alpine Bioventures

www.alpinebioventures.com [cached]

Mitchell H. Gold, MD
Founder & Managing Partner Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold's career in medicine and desire to transform scientific breakthroughs into a reality for patients. As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Provenge is now marketed worldwide by Valeant Pharmaceuticals (NYSE:VRX). Read more Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Oncothyreon (NASDAQ: ONTY) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. A Chicago native, Dr. Gold graduated from the University of Wisconsin and Rush University Medical School in Chicago and was a urology resident at the University of Washington. Dr. Gold is on Twitter @Alpine_Mitch Mitchell Gold speaks at Madison, WI Bioscience Vision Summit


HST Global

www.hstglobal.com [cached]

Dr. Mitchell Gold, CEO and President of Dendreon stated "The FDA approval of Provenge is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees."


About Us | Alpine Immune Sciences

www.alpineimmunesciences.com [cached]

Mitchell H. Gold, MD
Executive Chairman & Acting CEO Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold's career in medicine and desire to transform scientific breakthroughs into a reality for patients. As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Oncothyreon (NASDAQ:ONTY) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. Dr. Gold is currently the founder and managing partner of Alpine BioVentures. Dr. Gold is on Twitter @Alpine_Mitch Mitchell H. Gold, MD Executive Chairman & Acting CEO Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer. As CEO of Dendreon Corporation, Dr. Mitchell H. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Oncothyreon (NASDAQ:ONTY) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. Dr. Gold is currently the founder and managing partner of Alpine BioVentures. Dr. Gold is on Twitter @Alpine_Mitch


www.alpinebio.com

Mitchell H. Gold, MD - Founder & Executive Chairman
In addition to his role at Alpine Biosciences, Dr. Gold serves as the managing partner of Alpine BioVentures, a healthcare focused hedge/venture fund. Dr. Gold was previously the President and CEO of Dendreon, where he and his team secured FDA approval for Provenge, the world's first active cellular immunotherapy. Mitchell H. Gold, MD - Founder and Executive Chairman


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory